ANGLE Announces Positive Interim Evaluation of Ovarian Cancer Clinical Studies

ANGLE Announces Positive Interim Evaluation of Ovarian Cancer Clinical Studies
ANGLE has completed the planned interim analysis of two clinical studies, in Europe and the United States, evaluating its Parsortix system in women with ovarian cancer. The data has shown that the system can accurately distinguish malignant masses from benign tumors. Parsortix is ANGLE’s specialized platform technology that captures tumor cells circulating in blood — even when they are as rare in number as one in 1 billion — and harvests them for analysis. This early evaluation suggests that an assay using Parsortix technology could accurately distinguish between a malignant pelvic mass and a benign tumor, with the added benefit of providing valuable gene expression information that could help refine treatment decisions. Surgery for ovarian cancer is highly complex and it would be of significant clinical benefit to know in advance of surgery whether an abnormal pelvic mass is malignant or benign. If confirmed, this technology could transform risk assessment of ovarian cancer. The European arm of the study (NCT02785731) is being led by Robert Zeillinger, PhD, at the Medical University of Vienna. Patient enrollment in this study is now more than 90% and is expected to be completed in February. The U.S. arm of the study is being led by Richard Moore, MD, of the University of Rochester Medical Center, Wilmot Cancer Institute. Patient enrollment for this arm is ahead of schedule, with approximately 70% of the required patient sample enrolled and on target to be completed by the end of April. Headline data from the full studies is expected by mid-2017
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *